Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
- Study Title
- A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
- Teva Identifier
- C38072/3083 | 2010-024006-35
- ClinicalTrials.gov Identifier
- NCT01285323
- Study Status
- Completed
- Trial Condition(s)
- Eosinophilic Asthma
- Interventions
- Drug: Reslizumab | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 12 Years to 75 Years
- Trial Duration
- 03/01/2011 - 04/01/2014
- Phase
- Phase 3
